Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange traded fund launched on ...

ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) recently released a strong earnings report, and the market responded ...

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Second Quarter 2025 Results Key Financial Results Revenue: US$264.6m (up ...

Biotech group Neuren Pharmaceuticals has reported a 14% uptick in quarterly US sales of its Retts syndrome treatment Daybue.

Shares little changed from Wednesday’s record; ASX hammered on monopoly chatter, costs hit; Domain to exit sharemarket after ...

Shares little changed from Wednesday’s record; ASX hammered on monopoly chatter, costs hit; Domain to exit sharemarket after ...

Acadia Pharma (ACAD) is scheduled to announce Q2 earnings results on Wednesday, August 6th, after market close.

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.2 per share a year ago.

SAN DIEGO (AP) — SAN DIEGO (AP) — Acadia Pharmaceuticals Inc. (ACAD) on Wednesday reported second-quarter net income of $26.7 million. The San Diego-based company said it had net income of 16 cents ...

Neuren Pharmaceutical's reports boosted sales of the Rett syndrome drug Daybue, but two-thirds of US patients are yet to try it.